Pfizer (NYSE:PFE) Lowered to Neutral Rating by Daiwa Securities Group

Daiwa Securities Group downgraded shares of Pfizer (NYSE:PFE) from an outperform rating to a neutral rating in a report released on Thursday, Marketbeat reports. Daiwa Securities Group currently has $27.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also recently weighed in on the stock. HSBC reaffirmed a “buy” rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. UBS Group started coverage on Pfizer in a report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price objective on the stock. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Citigroup began coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price for the company. Finally, BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research note on Wednesday, December 10th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, thirteen have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $28.00.

Pfizer Stock Down 1.0%

Shares of NYSE PFE opened at $27.47 on Thursday. The company has a market cap of $156.16 billion, a price-to-earnings ratio of 20.19 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62. Pfizer has a 12 month low of $20.92 and a 12 month high of $27.94. The stock has a 50-day moving average price of $25.77 and a two-hundred day moving average price of $25.17.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion for the quarter, compared to the consensus estimate of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.25%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company posted $0.63 EPS. As a group, analysts forecast that Pfizer will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Institutional Trading of Pfizer

Several institutional investors have recently added to or reduced their stakes in PFE. Triad Wealth Partners LLC boosted its stake in shares of Pfizer by 1.9% in the 4th quarter. Triad Wealth Partners LLC now owns 20,466 shares of the biopharmaceutical company’s stock valued at $510,000 after purchasing an additional 386 shares during the last quarter. ETF Store Inc. lifted its holdings in Pfizer by 3.8% in the fourth quarter. ETF Store Inc. now owns 10,913 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 396 shares during the period. Mattern Wealth Management LLC boosted its position in Pfizer by 4.6% during the fourth quarter. Mattern Wealth Management LLC now owns 9,161 shares of the biopharmaceutical company’s stock valued at $228,000 after acquiring an additional 400 shares during the last quarter. Pines Wealth Management LLC grew its holdings in Pfizer by 4.4% during the 4th quarter. Pines Wealth Management LLC now owns 9,430 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 400 shares during the period. Finally, Peak Asset Management LLC raised its position in shares of Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 402 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Post-earnings bullishness: unusual call-option activity and an upbeat earnings outlook have put some investors on the buy side, supporting short-term sentiment. Read More.
• Positive Sentiment: Investor commentary sees a buying opportunity after the quarter — analysts and commentators highlight attractive valuation and the company’s ability to generate cash as reasons to consider PFE after results. Read More.
• Positive Sentiment: Capital return profile: coverage notes Pfizer returned about $9.8B to shareholders and remains a high-yield candidate for income investors, which supports the stock’s floor for dividend-seeking buyers. Read More. Read More.
• Positive Sentiment: Dividend/yield appeal: Pfizer appears on lists of high-yield dividend names, attracting income-focused investors even as growth questions persist. Read More.
• Neutral Sentiment: Longer-term growth outlook is mixed — analyses examine whether newly acquired and in‑pipeline drugs can offset a looming 2026–2030 patent cliff; outcome will determine medium-term revenue trajectory. Read More.
• Neutral Sentiment: “Is now the best time to buy?” pieces suggest re-evaluating Pfizer after earnings — these are informative to investors but stop short of a consensus buy/sell signal. Read More.
• Negative Sentiment: Analyst downgrade: Daiwa cut Pfizer from “outperform” to “neutral” and set a $27 price target, signaling limited near-term upside from their perspective and adding downward pressure. Read More.
• Negative Sentiment: Valuation / structural concerns: opinion pieces argue Pfizer could be a value trap if new product flow and M&A don’t offset fading COVID-era sales and patent expiries, which raises caution among some investors. Read More.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.